VeinRx Inc.
This article was originally published in Start Up
Executive Summary
VeinRx's balloon-controlled venous ablation technology is designed to address both the medical and cosmetic varicose vein markets. It is a single-use, catheter-based product for delivering a sclerosant to the diseased vein. The balloon prevents the chemical from migrating out of the treatment zone. Physicians thus have greater control over both the dosage and the treatment area. There's also a potential safety benefit since the sclerosing agent cannot disperse into the general circulation.
You may also be interested in...
Vein Device Companies Dig Deeper
Vein diseases such as deep vein thrombosis, pulmonary embolism and chronic venous insufficiency have historically been the province of drug therapies, but they shouldn't be, according to the clinical socieities and medical device companies that are trying to create a groundswell in interventional vein treatments. The field is starting to organize: on the clinical side, the first clinical trials ever to pit devices against drugs for DVT are in progress. At the same time, Covidien has drawn attention to the business opportunities in the field by acquiring three companies with venous devices.
New Devices for Varicose Veins
There's nothing even remotely sexy about varicose veins. Yet medical device companies and their investors are starting to view the opportunity for treating these bulging blue leg veins as downright alluring. The recent introduction of minimally invasive technologies, combined with shifting demographics and favorable reimbursements, are fueling talk of blockbuster potential for this hybrid clinical/cosmetic market.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.